Clinical Trial Update: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial [Phase 1]

View source ↗

Summary

Phase 1 proof-of-principle trial evaluating SOM230 (pasireotide) as an IGF-I action inhibitor for breast cancer chemoprevention in high-risk lesions has been co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Ductal Hyperplasia
• Atypical Lobular Hyperplasia
• Lobular Carcinoma in Situ

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: NYU Langone Health | Conditions: Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS) | Phase 1 | Status: COMPLETED